Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
about
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectivesTargeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trialsCurrent advances in intratumoral androgen metabolism in castration-resistant prostate cancer.Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer.Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.Cellular determinants and microenvironmental regulation of prostate cancer metastasis.Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.Prostate cancer: Developing novel approaches to castration-sensitive disease.Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy.Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer.Targeting the androgen receptor in triple-negative breast cancer.Sequencing Treatment for Castration-Resistant Prostate Cancer.Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxelComparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials.Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.Rapid bench to bed in management of metastatic prostate cancerSeizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers.Risk Factors for and Incidence of Seizures in Metastatic Castration-Resistant Prostate Cancer: A Real-World Retrospective Cohort Study.Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis.Drug development for noncastrate prostate cancer in a changed therapeutic landscape.Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.Mangiferin functionalized radioactive gold nanoparticles (MGF-198AuNPs) in prostate tumor therapy: green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy.Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens.Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.The Androgen Receptor: Is It a Promising Target?Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.Precision medicine applications in prostate cancer.Recent trends in the management of advanced prostate cancerMedical management of metastatic prostate cancerCombined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matchingNumber-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trialsA patient-derived explant (PDE) model of hormone-dependent cancer
P2860
Q28076911-428438F5-730F-4C47-ABFD-3473B99504F2Q36175852-7DA5F64A-A22B-4F87-B690-B68EC65C420FQ36970812-D8172CFA-1671-4825-91AE-BBA1F5204FB5Q38392787-A2B540A9-2FBE-4661-93BB-21CB8DE6828AQ38608844-D2D6E821-B076-4E84-9272-7AFADDB36D32Q38680652-8AAFCE11-A775-4CF7-830C-34861BCE6686Q38730590-9C1B827C-15FF-42D9-A433-01F57420C29CQ38775459-8BE95B18-A921-4BD7-8C84-D1B35DBFF1A2Q38797560-3937745A-8622-47CA-BE6C-334E166B9FECQ38801270-DA7ABE7A-7923-41FA-A424-E53257E4C355Q38927273-FD170F28-974C-4664-AE2C-64F124EE646EQ38970564-0E2CA898-E50F-4944-B2D1-FE7D511A2068Q38999707-01D321F8-3D77-4814-A778-BE6DDBB58384Q39002328-86740CFD-E9D8-406E-A4D2-BDDAB9AAB5AAQ40374954-BE8C7F21-48C1-434D-87F9-1636538F589DQ41044524-A4F0CE39-9D4C-4014-9696-2B8EB76C7720Q41709181-5ADFBC62-B9C4-43C4-B70C-E8F18B862A21Q42203821-04AD0950-D7D7-43A3-9E69-6F07E172BE00Q42386231-A0109605-1690-4493-A3BE-7F804A615E39Q46072230-26380B25-EE96-41A5-AC07-4577B4CBEBE7Q46095028-DBAB4B35-00AC-4CBC-A4F8-F0B063092ABCQ47109527-4312C3B7-5AD4-485D-8A88-D4E981D71C9CQ47685684-0A41E188-E7C9-409C-AC8E-65D4F179D22EQ47825566-E994A91B-BAAE-43FD-AD51-886F08D5ADFDQ48021007-AA97D685-030D-42AE-8B3E-0665B8C07B0BQ48189307-6FEE7A06-24B2-4731-A90F-02EECA39CE27Q48629219-D8D352E6-1331-47A0-92DE-DEC719BB2DDDQ49662817-A2D96175-45A0-4219-A89F-171686A8212CQ50203117-241B545D-450E-49A9-B6E2-4B57AAA38E62Q52677958-B6225778-C7C0-46F6-AD16-F0E6ADC5B169Q52744336-BFD4B4CA-F458-45FC-9961-1725AA2CA524Q53130565-1F56CFC3-193F-4014-A028-4E6C456B23FEQ55020070-1480FA78-A12B-4C42-904C-6B2A2799CBDDQ55439000-551FC87B-BC68-4CCA-805D-195C2ABCE89BQ57821875-A860C185-37DC-41C9-A421-9338726A3BF8Q58588895-6BA246A3-19F1-48C1-8636-7D5A651E7566Q58699993-7F088C02-7D66-4C1A-8714-EA860E352539Q58761734-6D3F4551-6E47-49E4-A857-B571636AE3F1Q58772979-2AAE23CC-FE05-4485-B092-4319F27DC104
P2860
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Enzalutamide Versus Bicalutami ...... tate Cancer: The STRIVE Trial.
@en
type
label
Enzalutamide Versus Bicalutami ...... tate Cancer: The STRIVE Trial.
@en
prefLabel
Enzalutamide Versus Bicalutami ...... tate Cancer: The STRIVE Trial.
@en
P2093
P356
P1476
Enzalutamide Versus Bicalutami ...... tate Cancer: The STRIVE Trial.
@en
P2093
Andrew J Armstrong
Andrew Krivoshik
Carl Olsson
Celestia S Higano
Curtis Dunshee
Kenneth Wu
Lawrence Karsh
Neeraj Agarwal
P304
P356
10.1200/JCO.2015.64.9285
P407
P577
2016-01-25T00:00:00Z